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ABSTRACT
PURPOSE: To compare the efficacy and side effects of two com-
binations of tropicamide and phenylephrine as mydriatics for 
ophthalmoscopy.
METHODS: In this prospective randomized controlled trial, 51 
Chinese outpatients were randomized to receive topical tropicami-
de 1.0% and phenylephrine 2.5% (Regime A), and 50 to receive a 
fixed combination of tropicamide 0.5% and phenylephrine 0.5% 
(Regime B). The change in horizontal pupillary diameter, subject 
discomfort upon instillation and the time elapsed between instilla-
tion and recovery from glare and near blur were studied.
RESULTS: After 60 minutes, the mean increase in pupillary diame-
ter was 3.56±0.65 mm with Regime A, and 3.04±0.62 mm with 
Regime B (P<0.01), but there was no difference in the proportion 
of subjects having a post-mydriatic pupillary diameter of 6 mm 
or larger (P=0.54). No subjects required additional instillation. 
Regime B was better tolerated (P<0.001). The median times elap-
sed between instillation and  recovery from glare or near blur was 
7 hours, without a significant difference between the two regimes 
(P=0.5).
CONCLUSIONS: Both regimes were effective and safe for ophthal-
moscopy. However, Regime B was better tolerated. Subjects may 
be reassured that the side effects of glare and near blur are likely to 
disappear by the following day.
(J Optom 2010;3:37-43 ©2010 Spanish Council of Optometry)
KEY WORDS: tropicamide; phenylephrine; mydriatics; glare; near 
blur.
RESUMEN
OBJETIVO: Comparar la eficacia y los efectos secundarios de dos 
combinaciones distintas de tropicamida y fenilefrina como midriá-
tico para oftalmoscopia.
MÉTODOS: En este ensayo clínico prospectivo, controlado y aleato-
rizado, se determinó aleatoriamente que 51 pacientes ambulatorios 
chinos recibieran por vía tópica tropicamida 1.0% y fenilefrina 
2.5% (Combinación A), y que otros 50 recibieran una combinación 
fija de tropicamida 0.5% + fenilefrina 0.5% (Combinación B). 
Como criterios de valoración se estudiaron: la variación del diáme-
tro pupilar a lo largo del meridiano horizontal, las molestias sufridas 
por los sujetos cuando les instilan las gotas y el tiempo transcurrido 
desde la instilación del midriático hasta que desaparece el deslum-
bramiento y la visión cercana borrosa.
RESULTADOS: A los 60 minutos, el aumento medio del diámetro 
pupilar fue 3,56±0,65 mm con la Combinación A, y 3,04±0,62 
mm con la Combinación B (P<0,01), pero no se halló ninguna 
diferencia significativa entre los dos grupos en cuanto al porcentaje 
de sujetos que lograron con el midriático un diámetro pupilar igual 
o superior a 6 mm (P=0,54). Ningún sujeto requirió la instilación 
de gotas adicionales para lograr la midriasis. Los sujetos toleraron 
mejor la Combinación B (P<0,001). En promedio, el tiempo 
necesario para que el deslumbramiento y la visión cercana borrosa 
desaparecieran fue de 7 horas, no observándose ninguna diferencia 
significativa entre los dos grupos (P=0,5).
CONCLUSIONES: Ambas combinaciones resultaron ser eficaces y 
seguras para ser utilizadas en oftalmoscopia. Sin embargo, los sujetos 
toleraron mejor la Combinación B. Los sujetos pueden estar tranqui-
los, pues es probable que los efectos secundarios de deslumbramiento 
y visión cercana borrosa hayan desaparecido ya la mañana siguiente 
al día de la instilación.
(J Optom 2010;3:37-43 ©2010 Consejo General de Colegios de 
Ópticos-Optometristas de España)
PALABRAS CLAVE: tropicamida; fenilefrina; midriático; deslumbra-
miento; visión cercana borrosa.
INTRODUCTION
Detailed examination of the lens, vitreous and retina 
requires adequate pupillary dilatation. The ideal mydria-
tic should show a rapid onset of action, achieve adequate 
mydriasis, permit a quick recovery, and not cause dis-
comfort or side effects. Tropicamide, an antimuscarinic 
agent, produces mydriasis within 20 minutes. Recovery of 
accommodation from its cycloplegic effects normally takes 
6 hours. Phenylephrine is a sympathomimetic having pre-
dominantly alpha-adrenergic activity. Its side effects include 
local irritation and hypertension due to systemic absorption.1 
Tropicamide 1% and phenylephrine 2.5% were supplied as 
separate preparations, and sequential instillation of one drop 
of each was required. Subjects reported different degrees of 
stinging sensation when these drops were instilled. Greater 
mydriatic effect could be achieved when these mydria-
tics were used in combinations.2,3 There were attempts to 
prepare fixed combinations from these two medications. 
However, solutions of tropicamide at a concentration of 
1% or above may precipitate if this is mixed with phenyle-
phrine.4 A fixed combination of these two medications at 
a low concentration–tropicamide 0.5% and phenylephrine 
0.5%–is chemically stable, with the advantage that only one 
drop of medication is required in each eye. This might be 
better tolerated by subjects and could save the staff time, 
especially at a busy outpatient clinic setting. Other possible 
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benefits of low-concentration preparations include a lower 
risk of cardiovascular side effects,5,6 and a faster recovery from 
blurring of near vision and glare.3 A randomized controlled 
trial was designed to compare the efficacy and side effects of 
these two regimes.
MATERIALS AND METHODS
This was a prospective, single-blinded, randomized, 
controlled trial. The study was approved by the hospital’s 
Clinical Research Ethics Committee and adhered to the 
tenets of the Declaration of Helsinki. Subjects were recruited 
among those patients who required comprehensive eye exa-
mination at the General Ophthalmology Clinic of the Hong 
Kong Eye Hospital. Chinese subjects, having dark brown 
irides, at least 18 years old, and a corrected near visual acuity 
of 20/400 or better were eligible to participate.  Subjects were 
excluded if they had diabetes mellitus, uncontrolled systemic 
hypertension, or a history of anterior segment trauma, pre-
vious ocular surgery, use of topical ocular medications other 
than artificial tears or allergy to mydriatics. Other exclusion 
criteria were: intraocular pressure above 21 mmHg, narrow 
anterior chamber angle, anterior segment abnormalities, 
abnormal pupillary light reaction, blepharoptosis, ocular 
motility defects, and instillation of topical anesthetics prior 
to pupillary dilatation during the study visit.
Written informed consent was obtained from those sub-
jects who satisfied the recruitment criteria.  Eligible subjects 
were randomized to receive either Regime A or Regime B. 
Regime A comprised the sequential instillation of one drop 
of tropicamide 1.0% (Mydriacyl; Alcon, Puurs, Belgium) 
and one drop of phenylephrine 2.5% (Mydfrin; Alcon, TX, 
USA) in each eye, whereas Regime B consisted of one drop 
of the fixed combination of tropicamide 0.5% with phen-
ylephrine 0.5% (Mydrin-P; Santen, Osaka, Japan) instilled 
into each eye.
The sample size was set to detect with 80% power a 
0.5 mm difference between the two groups in the mean 
change in horizontal pupillary diameters of the two eyes. 
Considering possible multiple comparisons, the maximum 
false-positive error was taken as 1% for two-sided tests using 
the Bonferroni procedure.  Around 50 subjects were recrui-
ted into each group.
One of the two mydriatic regimes, according to the 
randomization code, was instilled in the lower conjunctival 
fornices.  The lacrimal sacs were compressed for one minute 
after eye drop instillation to minimize systemic absorption.6 
Subjects were asked to grade the ocular discomfort they 
experienced at instillation time using a scale of 0 to 10; where 
0 indicates no discomfort at all, and 10 indicates maximal 
discomfort.
The study was conducted in the consultation rooms with 
controlled ambient illumination at photopic condition.  The 
horizontal pupillary diameter was measured to the nearest 
0.5 mm with a handheld infrared pupillometer (Colvard 
pupillometer; Oasis Medical, Glendora, CA, USA) immedia-
tely before, as well as 15, 30, 45 and 60 minutes after insti-
llation of the assigned regime. During the measurement, the 
subject was instructed to look at the red fixation light of the 
pupillometer, while the fellow eye was left unobstructed. The 
investigator responsible for pupillary-diameter measurement 
was masked to the regime the subjects received.  However, 
subjects were not masked as the number of instilled drops 
was different.  Sixty minutes after eye-drop instillation, an 
ocular examination was conducted by means of a slitlamp 
biomicroscope and a binocular indirect ophthalmoscope 
(All Pupil; Keeler, Windsor, UK). Any pupillary constriction 
as a result of the light of the indirect ophthalmoscope was 
noted.
The duration of symptoms of glare and blurred near 
vision after mydriasis were investigated. Subjects were asked 
to read a standard near visual acuity chart (Chart “2”, 
Logarithmic Near Visual Acuity Chart “2000”; Precision 
Vision, La Salle, IL, USA) with reading glasses, if required 
both before and 60 minutes after the instillation of the eye 
drops.  Those subjects who experienced post-mydriatic near 
blur were requested to read the near visual acuity chart again 
once every hour and record the result in a timetable given 
at the end of the eye examination, until they could read the 
same line achieved before mydriasis. Similarly, those subjects 
who experienced glare after pupillary dilatation were reques-
ted to check and record its progress once every hour, until no 
more glare was experienced.
Pulse rate, and systolic and diastolic blood pressure 
were measured using an automated sphygmomanometer 
(BP-8800C; Colin, Komaki City, Aichi, Japan) at baseline, 
and 30 and 60 minutes after instillation.
Data were analyzed using a computer statistical package 
(SAS version 9.1.3; Cary, NC, USA). Pupillary diameter 
data were checked for univariate and multivariate norma-
lity. For the purpose of the drug-efficacy comparison, the 
average increase in horizontal pupillary diameter observed 
in the two eyes of each subject quarter-hourly after instilla-
tion were analyzed using multivariate analysis of variance. 
Mydriatic response of the two eyes from the same subject 
are highly correlated, readings from the right and left eyes of 
one subject cannot be regarded as two independent samples 
for the analysis of variance. Taking the average increase of 
pupillary diameter of the same subject for computation does 
not affect the values of the means. The values of standard 
deviations are likely to be smaller and confidence intervals 
narrower. Multivariate analysis of variance was also used to 
compare the changes in pulse rate and blood pressure across 
the two groups (i.e., regimes). Discomfort scores were com-
pared using the Wilcoxon rank-sum test. The times elapsed 
between instillation and recovery from post-mydriatic near 
blur and glare were compared using the logrank test on their 
Kaplain-Meier survival functions. When a subject went to 
bed before recovery from glare or near blur, but had recove-
red from these effects on awakening, the last recorded time 
before going to bed was regarded as a censored observation.
RESULTS
Of the 101 subjects recruited, 51 were randomized to 
Group A and 50 to Group B.  Both groups were comparable 
in terms of age, sex, prevalence of hypertension and heart 
disease (Table 1). Pupillary diameters at baseline were similar 
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in both groups (Table 2). Twenty-five subjects had unequal 
pupil size at baseline (24.8%). Their baseline blood pressure 
readings and pulse rates were comparable (Table 3).
When the pupillary data were checked for normality, one 
outlier in group B was identified and removed, leaving a total 
of 49 subjects in this group. From 30 minutes after instilla-
tion, the mean increase in horizontal pupillary diameter of 
both eyes became significantly different, reaching 3.56±0.65 
mm with Regime A, and 3.04±0.62 mm with Regime B 
(P<0.01, Figure 1) at 60 minutes. Subjects who received 
Regime A had a larger post-mydriatic pupillary diameter 
(7.61±0.86 mm) than those receiving Regime B (7.22±0.80 
mm) (P=0.015). Most subjects attained a pupillary diameter 
of 6 mm or above during indirect ophthalmoscopy (98.0% 
with Regime A and 96.0% with Regime B; P=0.55). No 
subject required a second instillation or noticed any pupi-
llary constriction during binocular indirect ophthalmoscopy. 
Subjects on Regime A reported higher discomfort scores than 
those receiving Regime B (P<0.001).
Times for recovery from post-mydriatic glare and blu-
rring of near vision were analyzed using their Kaplain-Meier 
survival functions.  The latter did not follow any simple 
distribution model and, therefore, these data were compared 
using the non-parametric logrank test. On a first inspection 
the durations of these side effects appeared to be more pro-
longed with Regime A than with Regime B; however, the 
differences were not statistically significant neither for glare 
(P=0.53, Figure 2) nor for near blur (P= 0.48, Figure 3). The 
median duration was around 7 hours for both side effects. 
Glare could last up to 13 hours with either regime.  It could 
take as long as 15 hours to recover from near blur after insti-
llation of Regime A, and 13 hours with Regime B.
Subjects in both groups had minimal changes in pulse 
rate, systolic pressure and diastolic pressure after mydriasis 
(Figures 4, 5 and 6), and no adverse reactions were noted 
during the study.
DISCUSSION
Measurement of pupillary diameter using conventional 
methods, such as a millimeter ruler or a Rosenbaum pocket-
card pupil gauge is difficult and often inaccurate.7 With 
our local Chinese population, who have dark brown irides, 
pupillary measurement could be difficult since the color 
contrast between iris and pupil is low. Diffuse illumination 
using a hand torch, a direct ophthalmoscope or a slit-lamp 
biomicroscope often induces variable amounts of pupillary 
constriction due to the direct light reflex, reducing the repro-
ducibility of the measurement . The use of an infrared pupi-
llometer avoids the use of illumination, and the red fixation 
light of the pupillometer allows subjects to fixate steadily, 
without stimulating accommodation.  Based on its precision 
and reliability, the Colvard pupillometer was chosen for this 
clinical trial.8 During pupillary-diameter measurement, the 
patient was instructed to look at the fixation light while the 
fellow eye could see across the consultation room unobstruc-
ted. This avoided miosis due to near reflex, but allowed the 
measured pupil to respond to ambient illumination via the 
consensual reflex.
The differences in change in mean pupillary diameter 
observed from 30 minutes onwards were significant. In a 
study on preoperative mydriasis for cataract surgery among 
Chinese patients comparing the same mydriatic combinations 
TABLE 1 
Demographic data
 Regime A Regime B P
 (N = 51) (N = 50) 
Age (years) 60.04±16.88 61.36±15.34 0.84*
mean ± SD (18 to 86) (18 to 86)
(range)
Sex, M:F 16:35 15:35 1.0§
Hypertension n (%) 16 (31.4%) 19 (38.0%) 0.54§
Heart Disease n (%) 3 (5.9%) 5 (10.0%) 0.49§
Regime A = Tropicamide 1.0% and phenylephrine 2.5%; Regime B = 
Tropicamide 0.5% and phenylephrine 0.5%; *Mann-Whitney U test; 
§Fisher’s exact test.
TABLE 2 
Baseline photopic horizontal pupillary diameter including mean 
±SD and 95% confidence intervals (lower-upper limits). Values 
are in mm
 Regime A Regime B P*
 (N = 51) (N = 50) 
OD 4.09 ± 0.80 4.22 ± 0.74 0.40
 (3.86 − 4.31) (4.01 − 4.43) 
OS 4.06 ± 0.75 4.15 ± 0.78 0.69
 (3.85 − 4.27) (3.93 − 4.37) 
Regime A = Tropicamide 1.0% and phenylephrine 2.5%; Regime B = 
Tropicamide 0.5% and phenylephrine 0.5%; *Mann-Whitney U test
TABLE 3 
Pulse rate and blood pressure at baseline including mean ±SD
 Regime A Regime B P
 (N = 51) (N = 50) 
Systolic blood  
pressure (mmHg) 137.90±25.87 141.72±28.36 0.56
Diastolic blood  
pressure (mmHg) 70.98±11.54 72.50±12.15 0.43
Pulse Rate, min-1 74.43±13.98 69.42±7.59 0.09
Regime A = Tropicamide 1.0% and phenylephrine 2.5%
Regime B = Tropicamide 0.5% and phenylephrine 0.5%
*Mann-Whitney U test, §Fisher’s exact test.
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but instilled four times, Lam et al reported that the mydria-
tic effect (i.e., increase in pupil diameter) with tropicamide 
1.0% plus phenylephrine 2.5% (3.70±0.97 mm) was greater 
than that observed for the fixed combination of tropicamide 
0.5% and phenylephrine 0.5% (3.32±1.00 mm).9  Weiss and 
co-workers also noted a 3.56±1.26 mm increase in pupillary 
diameter with tropicamide 1% plus phenylephrine 2.5% 
in diabetic patients.10 However, there was a large variability 
regarding the time required to achieve maximum mydriasis 
(from 10 to 135 minutes).  Forman did not find a clinically 
significant difference in mydriasis resulting from the use of 
a mixture of tropicamide 0.75% and phenylephrine 2.5% 
(mean 7.4 mm) or of separate tropicamide 1.0% and phen-
ylephrine 10% (mean 7.6 mm) in Caucasian eyes.11 Sinclair 
et al. reported a greater mydriatic effect with tropicamide 
1.0% and phenylephrine 5.0%, compared with tropicamide 
1.0% and phenylephrine 2.5%.4 However, in this study the 
use of a topical anesthetic may have enhanced the effect of 
the dilating drops.  Apt and Henrick demonstrated that the 
instillation of topical proparacaine before mydriatics could 
bring about an additional mydriasis of 1 mm,12 while Ghose 
et al showed that the time to attain a 6 mm pupillary diame-
ter was shorter if an additional drop of topical lidocaine was 
instilled.13 In this study, subjects who had received a topical 
FIGURE 1
Changes in average horizontal pupillary 
diameter observed 15, 30, 45 and 60 
min after instillation of Regime A and of 
Regime B.  Vertical lines through the data 
points represent ±1 standard deviation 
from the mean. 
FIGURE 2
Kaplan-Meier survival function on the 
recovery from glare after mydriasis. 
Regime A = Tropicamide 1.0% and phenylephrine 2.5%; 
Regime B = Tropicamide 0.5% and phenylephrine 0.5%; 
*P<0.01
The y-axis indicates the probability of suffering from post-dilatation glare and the x-axis 
indicates the time for recovery.  With either regime, the median time for recovery was 7 
hours, the range being 0 to 13.3 hours with Regime A and 0 to 13.2 hours with Regime B 
(P=0.53).
Time after instillation (min)
Ch
an
ge
 in
 d
ia
m
et
er
 (m
m)
Time for recovery (hr)
Pr
ob
ab
ili
ty
 o
f g
la
re
Regime A
Regime B
Censored
Regime A Regime B
Mydriatic Combinations for Ophthalmoscopy: Lam PTH et al.   41
J Optom, Vol. 3, No. 1, January-March 2010
anesthetic prior to pupillary dilatation, e.g. for gonioscopic 
evaluation or Goldmann applanation tonometry, were exclu-
ded. Our results could be applicable to the clients attending 
general optometry clinics where topical anesthetic was not 
available.
In prior studies on pharmacological mydriasis with 
healthy volunteers, the two eyes of the same subject received 
different regimes,13-15 or a different regime is given to both 
eyes again after a wash-over period, e.g. cross-over study.12 
These methods effectively control intra-subject variability, 
reducing the sample size. In the clinical setting, however, 
subjects usually receive the same mydriatic regimes in both 
eyes and they seldom need to return for ophthalmoscopy 
within a short period. In this trial, we compared the efficacy 
of the two regimes using the average increase in horizontal 
pupillary diameter observed in both eyes. Practically, this has 
avoided some possible bias arising from the selection of the 
readings from one eye for analysis, when the baseline pupi-
llary diameters of both eyes were different. Lam, Thompson 
and Corbett showed that 19% of subjects in their study had 
physiological anisocoria,16 and the prevalence in the present 
study was even higher (24.8%). Bias could also arise from 
FIGURE 3
Kaplan-Meier survival function on the 
recovery from blurred near vision. 
The y-axis indicates the probability of suffering from post-dilatation blurred near vision 
and the x-axis indicates the time for recovery.  With either regime, the median time for 
recovery was 7 hours, ranging from 0 to 13.6 hours with Regime A and 0 to 15.2 hours with 
Regime B (P=0.48).
FIGURE 4
Change in systolic blood pressure obser-
ved 30 and 60 minutes after drug insti-
llation. Error bars represent SD. There 
was no significant difference between the 
two regimes. 
Regime A = Tropicamide 1.0% and phenylephrine 2.5%
Regime B = Tropicamide 0.5% and phenylephrine 0.5%
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choosing the eye that was the first or the second to receive 
the regime.  Lowenstein cautioned against the dilution effect 
provoked by reflex tearing caused by instillation of mydriatic 
to the first eye.17 Excess tears in the conjunctival fornix could 
diminish the amount of mydriatic reaching the second eye.
In the literature, various endpoints were used to define 
adequate pupillary dilatation when evaluating mydriatic 
regimes.3,12,13,18,19 Using the Schepens’ small pupil indirect 
ophthalmoscope,20 together with modern condensing lenses, 
the observation of the retinal periphery should not pose any 
difficulty with a 6 mm or larger pupil. In this study, 97% 
of subjects attained a pupillary size of 6 mm or above at 60 
minutes and no subject from either group required an addi-
tional instillation.
Blurring of near vision after mydriasis may affect the 
subjects’ working and reading ability, while glare may 
affect walking stability and safety, especially in the elderly.21 
Previous studies have also reported a drop in visual function 
after mydriasis. Eyeson-Annan et al. evaluated glare and 
the drop in reading ability after pupillary dilatation using 
FIGURE 5
Change in diastolic blood pressure obser-
ved 30 and 60 minutes after drug instilla-
tion. Error bars represent SD.
FIGURE 6
Change in diastolic blood pressure obser-
ved 30 and 60 minutes after drug instilla-
tion. Error bars represent SD.
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topical phenylephrine 10% alone or in combination with 
tropicamide 1.0%.3 They showed that the effects were 
greater with the combined regime. However, the duration 
for recovery from these effects was not specified. Reversal 
of mydriasis with thymoxamine could have sped up the 
recovery from mydriasis. Paggiarino et al. also found that 
30% of eyes still experienced a reduction in their amplitude 
of accommodation 7 hours after instillation of tropicamide 
0.5% and phenylephrine 2.5%.2 Subjects with brown eyes 
required longer recovery times than those with blue eyes. 
Reduced accommodative amplitude,21 reduced visual acuity 
and increased glare sensitivity have been reported after the 
use of tropicamide 1.0%.22 These studies involved young 
volunteers (under 35 years) and, therefore, their results 
could not be generalized to our subjects, whose mean age 
was above 60.
The effects on visual function were evaluated in this 
study using two subjective measures – blurred near vision, 
based on the duration of reduced reading ability, and glare, 
which was based on subjective sensation. Both regimes 
induced post-mydriatic near blur and glare, with a median 
duration of around 7 hours. However, there were large inter-
subject variations, ranging from no visual disturbances to 
side effects lasting up to 15 hours. The duration of visual 
disturbances was, in any case, above the 4-to-5-hours stated 
in Regime B’s product insert.23 It would be therefore prudent 
to warn subjects that their vision may be affected for the rest 
of the day and that most likely it will be back to normal by 
the next morning, regardless of which mydriatic regime was 
being used.
Subjects receiving Regime A reported higher discomfort 
scores.  This could be due to a higher concentration of drugs 
in this regime (phenylephrine in particular),1 to the mere ins-
tillation of four drops in this regime, or to a combination of 
these two factors. There were minimal changes in pulse rate 
and blood pressure after mydriasis in both groups. Neither 
regime caused any significant cardiovascular side effects. 
Lam et al. showed that these regimes were safe in a cohort of 
cataract patients whose mean age was 73 years.9
In conclusion, Regime A had a greater mydriatic effect 
than Regime B. Using a threshold of 6 mm or more as 
criteria for adequate pupillary mydriasis, we did not find a 
significant difference between the two regimes in terms of the 
proportion of subjects who achieved this threshold pupillary 
size. The use of one single drop of the fixed combination of 
tropicamide 0.5% and phenylephrine 0.5% appeared to be 
as effective (in clinical terms) but much better tolerated than 
the use of one drop of tropicamide 1% plus one drop of 
phenylephrine 2.5% in subjects with dark irides for ophthal-
moscopy. Subjects should be warned that the side effects of 
glare and near blur may last for the rest of the day but are 
likely to have disappeared by the next day.
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